Use of RAB31 inhibitors in the preparation of products for preventing and / or treating cardiovascular diseases
RAB31 inhibitors address the inadequacies of current treatments by reducing inflammatory infiltration and fibrosis, improving cardiac function and remodeling post-myocardial infarction, offering a safer and more effective treatment.
Patent Information
- Application Number
- CN202311682352.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-08
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-12-08
AI Technical Summary
Current treatments for ventricular remodeling after myocardial infarction are inadequate due to complex pathogenesis and high mortality rates, with existing methods not being sufficiently safe and effective.
Utilizing RAB31 inhibitors, such as nucleic acid molecules, small molecule chemical drugs, or gene editing systems, to target and inhibit the RAB31 gene or protein, reducing inflammatory infiltration, cardiomyocyte loss, and myocardial fibrosis, thereby improving cardiac function and remodeling.
RAB31 inhibition significantly reduces inflammatory infiltration, cardiomyocyte loss, and myocardial fibrosis, effectively treating ventricular remodeling and myocardial infarction, providing a safer and more effective treatment strategy.
Smart Images

Figure CN118078996B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of a RAB31 inhibitor in preparing a product for preventing and / or treating cardiovascular diseases. Background Art
[0002] Cardiovascular disease is the number one killer of human health. Ischemic heart disease is the main cause of death from cardiovascular disease. Myocardial infarction (MI) is a common type of ischemic heart disease. Blockage of myocardial blood supply for more than 30 minutes will cause changes in the ultrastructure and dysfunction of various organelles, leading to irreversible damage to myocardial cells and even death.
[0003] Acute myocardial infarction (AMI) is a clinical emergency and critical illness that seriously affects human health. In recent years, the incidence of myocardial infarction has shown a clear upward trend in my country, and the mortality rate has shown a rapid upward trend since 2005, which has become a major public health issue. Ventricular remodeling (VR) after acute myocardial infarction refers to the process of changes in the size, shape and organizational structure of the ventricles and the morphology and structure of myocardial cells, which is an important cause of heart failure and patient death. Therefore, inhibiting ventricular remodeling after myocardial infarction is an important way to prevent and treat myocardial infarction. At present, there are many methods for treating ventricular remodeling, and certain progress has been made. However, due to its complex pathogenesis and drug side effects, the treatment effect is still not ideal and the mortality rate is still high. Therefore, it is urgent to find safer and more effective prevention and treatment strategies.
[0004] Rab-related protein 31 (RAB31) belongs to the RAS superfamily and is a member of the small molecule GTPase family. It is mainly localized in the trans-Golgi network and endosomes in cells, and plays a regulatory role in physiological processes such as endocytosis and exocytosis, vesicle transport, membrane targeting and fusion. In the process of cell vesicle circulation, RAB31 mediates the transport of vesicles from the Golgi apparatus to early and late endosomes. At present, many studies have reported that RAB31 plays a role in promoting tumor proliferation in malignant tumors. For example, RAB31 is strongly overexpressed in estrogen receptor α-positive breast cancer samples and promotes the proliferation of breast cancer cells; RAB31 is one of the important genes affecting the development of glioblastoma multiforme and is upregulated in glioblastoma; RAB31 is overexpressed in gastric cancer substances and interacts with GLI1 to act as an oncogene in the occurrence and development of gastric cancer; in addition, RAB31 is highly expressed in pancreatic cancer, is associated with the low survival rate of patients, and is an effective prognostic biomarker in pancreatic cancer; RAB31 is highly expressed in cervical cancer cells and tissues, and reducing the expression of RAB31 can inhibit the invasion and metastasis of cervical cancer cells, while overexpression of RAB31 promotes the invasion and metastasis of cervical cancer cells.
[0005] In recent years, studies have found that RAB31 can promote the formation of intraluminal vesicles and inhibit the degradation of multivesicular endosomes, thereby promoting the secretion of exosomes. RAB31 promotes the endocytosis of TGF-β receptor II, activates the TGF-β pathway, activates hepatic stellate cells, and leads to liver fibrosis.
[0006] However, the effect of RAB31 on myocardial infarction has not been reported. Summary of the invention
[0007] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a use of a RAB31 inhibitor in the preparation of a product for preventing and / or treating cardiovascular diseases, in order to solve the above-mentioned problems.
[0008] To achieve the above purpose, the present invention specifically adopts the following technical solutions.
[0009] The first aspect of the present invention protects the use of a RAB31 inhibitor in the preparation of a product for preventing and / or treating cardiovascular diseases.
[0010] Preferably, the cardiovascular disease is ischemic heart disease, and more preferably, myocardial infarction.
[0011] Preferably, the RAB31 inhibitor refers to a substance that can inhibit the transcription or translation of the RAB31 gene, or can inhibit the expression or activity of the RAB31 protein.
[0012] More preferably, the RAB31 inhibitor is selected from one or more of nucleic acid molecules, small molecule chemical drugs, antibody drugs, polypeptides, proteins, nucleic acid constructs, interfering lentiviruses, interfering adeno-associated viruses and gene editing systems.
[0013] Further preferably, the nucleic acid molecule is any one or more of the following: antisense oligonucleotide, double-stranded RNA or shRNA.
[0014] More preferably, the RAB31 inhibitor is a nucleic acid molecule, and the target sequence of the nucleic acid molecule comprises the sequence shown in SEQ ID No. 1. Preferably, the nucleic acid molecule comprises the following elements: LoxP-target sequence-LoxP.
[0015] Further preferably, the RAB31 inhibitor is a nucleic acid construct, and the nucleic acid construct comprises the sequence shown in SEQ ID No.1.
[0016] Further preferably, the gene editing system is selected from one or more of the Cre-Loxp system, the Flp-FRT system, the Dre-ROX system, the vCre-vloxp system, the sCre-sloxp system, the CRISPR / Cas9 system, the CRISPR / Cas12 system, and / or a CRISPR / Cas-derived single-base editing system.
[0017] More preferably, the RAB31 inhibitor is a gene editing system, and the gene editing system uses the sequence shown in SEQ ID No. 1 as the target sequence.
[0018] Preferably, the RAB31 inhibitor has the effect of preventing and / or treating myocardial infarction through at least one of the following:
[0019] Reduce inflammatory infiltration of myocardial cells;
[0020] Reduce cardiomyocyte loss;
[0021] Inhibits cardiac function decline;
[0022] Inhibit myocardial fibrosis;
[0023] Improve cardiac remodeling after myocardial infarction.
[0024] Preferably, the RAB31 inhibitor is the only active ingredient or one of the active ingredients of the product.
[0025] The second aspect of the present invention protects a nucleic acid molecule for reducing the expression of the RAB31 gene, wherein the target sequence of the nucleic acid molecule comprises SEQ ID NO.1.
[0026] The third aspect of the present invention protects substances related to the nucleic acid molecules as described above, and the substances include one or more of the following:
[0027] 1) A nucleic acid construct, wherein the nucleic acid construct comprises the nucleic acid molecule as described above;
[0028] 2) A gene editing system, wherein the gene editing system uses the nucleic acid molecule as described above as a target sequence and knocks out; or, comprising the nucleic acid construct described in 1);
[0029] 3) A cell line, comprising the nucleic acid molecule as described above; or, comprising the nucleic acid construct as described in 1); or, obtained by transfecting a host cell with the gene editing system as described in 2);
[0030] 4) A pharmaceutical composition comprising the nucleic acid construct described in 1); or, the gene editing system described in 2); or, the cell line described in 3).
[0031] The fourth aspect of the present invention protects the use of the nucleic acid molecule as described above or the substance as described above in the preparation of a product for preventing or treating cardiovascular diseases; and / or, in the preparation of a kit for reducing the expression of the RAB31 gene.
[0032] Preferably, the product for preventing or treating cardiovascular diseases has at least one of the following effects:
[0033] Reduce inflammatory infiltration of myocardial cells;
[0034] Reduce cardiomyocyte loss;
[0035] Inhibits cardiac function decline;
[0036] Inhibit myocardial fibrosis;
[0037] Improve ventricular remodeling after myocardial infarction.
[0038] The fifth aspect of the present invention protects a method for screening drugs for preventing and / or treating cardiovascular diseases, the method comprising: taking RAB31 as a drug target, and searching for substances that can inhibit or block the expression and / or function of RAB31 as candidate drugs.
[0039] A sixth aspect of the present invention protects the use of the RAB31 gene as a target in the preparation of a product for the prevention, treatment or diagnosis of cardiovascular diseases.
[0040] Compared with the prior art, the present invention has the following beneficial effects:
[0041] The present invention first discovered that RAB31 can be used as a potential target site for screening drugs for preventing or treating cardiovascular diseases, especially for screening drugs for myocardial infarction. In addition, it was found that inhibiting the expression of the RAB31 gene can specifically inhibit and reduce myocardial cell inflammatory infiltration; reduce myocardial cell loss; inhibit cardiac dysfunction; inhibit myocardial fibrosis; thereby treating ventricular remodeling after myocardial infarction, and then effectively treating cardiovascular diseases, especially myocardial infarction. In summary, RAB31 has opened up a new direction and new theoretical basis for studying new targets or new treatment strategies for cardiovascular diseases, especially the prevention or treatment of myocardial infarction. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1A This is one of the graphs showing the effect of knocking out RAB31 on the cardiac function of mice with myocardial infarction in Example 2 of the present invention.
[0043] Figure 1B The second figure shows the effect of knocking out RAB31 on the cardiac function of mice with myocardial infarction in Example 2 of the present invention.
[0044] Figure 1CThe third figure shows the effect of knocking out RAB31 on the cardiac function of mice with myocardial infarction in Example 2 of the present invention.
[0045] Figure 2A Shown are HE staining images of the hearts of mice in each group after RAB31 was knocked out in Example 2 of the present invention.
[0046] Figure 2B Shown is a statistical graph of the cardiac index of each group of mice after RAB31 knockout in Example 2 of the present invention.
[0047] Figure 3A Shown are cross-sectional images of heart tissues of mice in each group detected by Masson staining after RAB31 knockout in Example 2 of the present invention.
[0048] Figure 3B It shows the statistical graph of cardiac tissue fibrosis in mice after knocking out RAB31 in Example 2 of the present invention.
[0049] Figure 4 It shows the construction strategy of the targeting vector in Example 1 of the present invention. Among them, wildtype allet is the allele of RAB31, Targeting vector is the targeting vector; Targeted allele is the targeting allele; Conditional KO allele is the specified knockout allele (after Neo deletion); Constitutive KO allele is the specified knockout allele (after Cre recombination); SDA (self-deletion anchor) site, Homology arm is the homology arm, exon of mouse Rab31 is the mouse Rab31 exon, and cKO is the knockout region.
[0050] Figure 5 Shown is a schematic diagram of the linearized targeting vector in Example 1 of the present invention. DETAILED DESCRIPTION
[0051] The present invention accidentally discovered that the RAB31 gene knockout mouse (Rab31 - / - ) were used as the subjects to study the myocardial infarction model by blocking the left anterior descending branch of the mouse heart. The results showed that compared with WT mice (Rab31 + / +) compared with the control group, the cardiac ejection fraction, short axis contraction rate, inflammatory cells, cardiac index and degree of fibrosis of RAB31 knockout mice were significantly suppressed, and the cardiac function was significantly improved; while the phenotypes of WT mice and RAB31 knockout mice were opposite. It shows that the RAB31 gene can promote and accelerate the occurrence and development of cardiovascular disease, RAB31 can be used as a drug target to screen drugs for preventing or treating cardiovascular disease, and RAB31 inhibitors can be used to prepare drugs for preventing or treating cardiovascular disease. On this basis, the present invention was completed.
[0052] The first aspect of the present invention protects the use of a RAB31 inhibitor in the preparation of a product for preventing and / or treating cardiovascular diseases.
[0053] The RAB31 gene number in the NCBI database is NM_133685; the number in the Ensembl database is ENSMUSG00000056515, and it is located on mouse chromosome 7; a total of 7 exons were identified, starting from the start codon ATG of exon 1 and ending with the stop codon TGA of exon 7 (Transcript: ENSMUST00000070673).
[0054] Preferably, the products include medicines, health products and foods.
[0055] Preferably, the RAB31 inhibitor is used alone or in combination with other drugs. That is, the RAB31 inhibitor can be used as the only active ingredient or one of the active ingredients of the product. The form of the product is not particularly limited and can be in the form of common solid, liquid, gel, semi-fluid, aerosol, etc.
[0056] Preferably, the RAB31 inhibitor generally includes a substance that can inhibit the transcription or translation of the RAB31 gene, or can inhibit the expression or activity of the RAB31 protein. For example, RAB31 can be partially inhibited, that is, the expression and / or function of RAB31 is reduced; it can also be completely inhibited, that is, the expression and / or function of RAB31 is substantially completely eliminated. For example, the RAB31 inhibitor can be a nucleic acid molecule, a small molecule chemical drug, an antibody drug, a polypeptide, a protein, a nucleic acid construct, an interfering lentivirus, an interfering adeno-associated virus, and a gene editing system. The nucleic acid molecule can be, but is not limited to, an antisense oligonucleotide, a double-stranded RNA, or a shRNA; further, after the double-stranded RNA is synthesized by a chemical method, it is injected into the human body to silence the RAB31 gene by RNA interference to treat cardiovascular diseases; it is also possible to design and construct a mutant of RAB31, which enters the cell after injection to compete for the substrate of the RAB31 prototype, thereby inhibiting the function of RAB31 and achieving the purpose of treatment; the small molecule chemical drug targets RAB31.
[0057] Preferably, the RAB31 inhibitor is a nucleic acid molecule, and the target sequence of the nucleic acid molecule comprises the sequence shown in SEQ ID No. 1. More preferably, the nucleic acid molecule comprises the following elements: LoxP-target sequence-LoxP.
[0058] GACACGGGGGTTGGGAAATCCAGCATTGTGTGTCGTTTTGTCCAGGATCACTTTGACCACAACATCAGCCCCACTATTGG(SEQ ID NO.1)
[0059] More preferably, the nucleic acid molecule further comprises one or more of a screening marker and SDA. The screening marker is selected from a positive screening marker and a negative screening marker, the positive screening marker is Neo, and the negative screening marker is DTA.
[0060] More preferably, the nucleic acid molecule further comprises a first homology arm and a second homology arm, the first homology arm is the first intron of the RAB31 gene, and the second homology arm is the second intron of the RAB31 gene.
[0061] Further preferably, the nucleic acid molecule includes the following elements: DTA-LoxP-target sequence-Neo-LoxP, specifically, the nucleic acid molecule includes the following elements: DTA-first homology arm-LoxP-target sequence-SDA-Neo-SDA-LoxP-second homology arm. Among them, LoxP and SDA are conventional sequences of targeting technology, the first homology arm is the first intron of RAB31, and the second homology arm is the second intron of RAB31. The size of the first intron inserted into the 5'-loxp site is 50418bp, and the size of the second intron inserted into the 3'-loxp site is 4444bp.
[0062] The loxP sequence is as follows:
[0063] ATAAC TTCGTA TAGCAT ACATTA TACGAA GTTAT(SEQ ID NO.2)
[0064] The SDA sequence is as follows:
[0065] TAA CTTTAA ATAATG CCAATT ATTTAAAGTTA(SEQ ID NO.3)
[0066] First homology arm
[0067] TGTTTCT TCATTC TTCGCT CGCTCT AGCCAT AAGCAT CTCCGAAACCCT GCTTTCTCTGTACTGACC GTAGGC TGGACC CCACCG GTATCG GTTATCAGCTAC CTCCCT GGTTTG CAAACTCCATTA GAGGGA GGTGGT AGGCTA CCTTTC CTGGCC TGCAGGGTTCCC AGACAC AGTAGG GAGGGTCTGAAC ACTCAG AGGTGC CCACCCACGTCCAACCCC AGCACG CAGGGC TCTGAA GCAGAT GCTCCACCTGGC TCTCCTCCCTCA CATGTTTTTAGG TCACAC CCAGGA TCATCC CTATTC TTTACCCCAAAAGTGCTG CTTGGA GAGAGCTGCCCT TAGTTC TCTTGG CTGGAG AACTAT GTACTTCCTTGTACTTCT TTATTC TTTGGACTCTCT GCCGGG CTCTCA GGGTGT TGTGGTGGCTCC GCCCCT GCCATGCACCAG CCATGACAGATG TTACAT CCTCTC AATTGACATGCT CACCTG GGGCGC ATGCAT GGGGGCGTGGCGGAGAGC TCCACC CTAAGTCCATTC CACAGA TCAGCT GAGCAG AGCCGG CCTGAAGGCCAGCCCTTG AAATACCCTTCA TGGTGA AAGCGC TAAGCT GTTTTA CGATTA TTAACTCCAGTCCTTGCCTTCTGC AGATGG CTCAAG TGAAAC GCCAGC TTTTTT GGTGAGCTAGAGAAGCAAGATGAT CATCTG TCAGAG GGCAAC TTGGGG GAGTTC TCTTCT ATCAAGAGTGTCCTGGGGATTGAA CTCAGT TCATCC ATCATT CTTCAT GTACCC GTTTTCTAAGCC AGTTTCTCAGCCACTTGA TTAGAA TCTTTC AAAAAA AAATTG TATGGATATTTT GTCCAA ATGTATTTTCCGTGCATC ATGTTT ACGCAATTGCCT GTAGAGACCAGA AGAGGA TATTAA GTCCCAGATGTCCAGTGG AACTGG GATCAC AGATGTTTGTGG GCTGTT GCGTTG TGGTGC TTGGAACTGAACCTGGGT CTTCTG CAAGAGCAGCAA GCATTC TTAACT ACTGAG CCATCT TGTCAGCCTAAAACTTTG TTTTTGTTTTTT TGTTTT TGTTTT TAATCA CACCTT TAGGGG TTGGGAATGTAACTCAGTTGGTAG TAGAGT GGGTGA AGTGCA TGAAGC TCTCTC TCTGGGTTTGATCCCTAGTGATAT GTAAGC CAGGCT TGGTGG TACATC ACTGCA GTCCTG GCACTTGAGATGTGGAGGTATGAT CAGTTC GAGATT ATCCTA ATCCAT AGGAAG CTTGAGGCTAGC TTGCGCTAGGGATACTCT CATAAT AAATAG ATAAAT AAATAA AGTCACATAGGA GAACCA TACACAACTCTTAAGTAT CTGGGT CACTCA GCTTTT TGTTTCTATGGA AACCTC CCTGGG ACAAAGCAGGAGTGGTTT ATTTTG TCTCAT AGTTTCAAAGGG TCAGTC CATCGT TGGCCA AAAGCTCTGGGGTTTTTA GCTTGA GCACACAATGCA ATTTAA TTGGGT ATCTCT GCCTGT GGGTTCCCCACCCACCTG CCCAGAGGGGGC TCCAGC TATTTC TGCCTA GGCTTA CATTGT TTCTTTCTTCCTCCGTGTGCCTTA TGCTGA TTTGTG AGTCTC AGGCAT GGATTG(SEQ ID NO.4)
[0068] The second homologous arm
[0069] TGTTCG GACAGA ATACCT TGGCAG CAGGAG CATATA GTGGAA GTGAGCTGTTGC TAGCCTTGTAGG GGTCAA GAAACA GAAAAG GAGAAG ACAGGA AGAGGCTGGGAC AAGATA GAGCAT CTAAGGACACGCCCATTG TGACTC GCTTCC TCTACCTAGACC CTCTTC CTACTT TTCAAT AATGTC CTCATATGATAA ATGCTT CAAAGGATTCAT CTATTC ATCATC AGGTCA GAGCCC TCATGA TCTAACAGTTTCTGGAAATGCCCC TGTAGA CACACC CACAGG TGTGTT CCACTA TCCCAT TAGGTATCTGTCCACCACAGCCAA ATTGGA GAATTG AGAGAT CCGTGG ATGTGG AGCACAGAGGGTGTGGCC ACCAGC CAGGTACATGCT ATGGGG TCACGG TCTCAA GCTTCA
[0070] GGATAT CTGAAGACTTAT TATAT TGTTAT TTCGGG AAGCTC TAGGGG TGCAGC
[0071] TTTCAT GCCCGG ACAGATAAGGCC CACCTT ATTTGC CTTGCT GGATTG TCTTAC
[0072] CTGCCT GACCCT GTGGAC ATCCCAGTTAAG TCCCTG ACCTA GAGTGA ATTGTG
[0073] ATGGTT TCCTCA GGTCAG AGCACA CAGGTAGCCACA GAGCTG CAAACT TGACTC
[0074] AGATCA AACCTA GCAGAG TTGGGT GTATGG CCTTAGTCATAC AGTGCT TGTACA
[0075] GCATGG ATGTGC GCTGCC AAAACC AACCAG ACAGGC AGATGACAAAGC AAGCCA
[0076] GTCTGT GCTATA AGCTAC CCAGTT CTTCCT ATCAGA ATCATG GTTGTAAAAGAG
[0077] CCTCAT TTCTCA TCAGCG GCATTA ACCCAC ATCACC GCAGTG ACACAC
[0078] TGATTGTGAAGT GCACTG ACTCAG AGGCAG CTATGC CACGGG CTATGT CCAGGC
[0079] ATGAAA GCTGCATCCCTT GAGCTT CCTGCA CAGCCT GCACAC ACGATC ATGTAT
[0080] GCAGCA GCTCTG TGAGTAGGTGTT TCTTCC CCACAG AAGTTG TGATCT TGTGAA
[0081] ACTTGT TTTACT ATATTA CAGAAGAGTATT TACTGG GGGAGG GTGATG CTTGCA
[0082] CACACA GCACAG TGCACA CGTGGA GGTCAGAGGACA ACTTGA AGGAGT TGATTC
[0083] TCTCCT TCTATC CTGTGG GTCCTG AGGGTC AAACTCAGGGTT TCAGGC TTGGTG
[0084] GCACAC ACTGTG TTATGA GTCTAC TCAGTG TTCCAT GGTGGATGCTAT GTTCTT
[0085] GTATAA CTTTCT ATAGAC CTAATT TTTTTT CTTTTC TGTTTT ATTTTTTAAAGA
[0086] TTTATT TATTTA TTTCAT GTATGT GAGTAC ACTGTT GCTATC TTCAGA
[0087] <h2 style=";text-align:left;direction:ltr">CACACCAGAAGA GGGCAT TGGATC CCCATT ACAGAT GGTTGT GAGCCA CCATGT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0088] <h2 style=";text-align:left;direction:ltr"> GGTTGC TGGGAATTGAAC TCAGGA CCTCTG GAAGAG CAGTCA GTGTTC TTAACC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0089] <h2 style=";text-align:left;direction:ltr"> ACTGAG CCATCT CTCCAGCCCACT GTTTTT TGGTTG TTTTTG TTGTTG TTGTTT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0090] <h2 style=";text-align:left;direction:ltr"> TTAAAT GAATGA GATACT TTAGCCCATAGA AGAAAG TCTATT AAATTA TTAAAT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0091] <h2 style=";text-align:left;direction:ltr"> ATTCTG TGTATT TGGTTT TTACCC CTTTATGAGCAC TAAGAA AATAAA TGCTTA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0092] <h2 style=";text-align:left;direction:ltr"> TTCAGA GAAAAT AGGTAG ATAAGG ATAGCC AGTAGTTTCTGA CTCATG CCTTGA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0093] <h2 style=";text-align:left;direction:ltr"> AGTCCC TCCTTT GTGATA GAAGCA TACGTG TGTTTT GTTTTTTATCCC TCTGCT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0094] <h2 style=";text-align:left;direction:ltr"> GGATAT TCTGTG TCAACT TGACAC AGGCTA AAGTCA TCTCAG GAGAGAGAACCT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0095] <h2 style=";text-align:left;direction:ltr"> CGATTG TGAACA TTGCTC CATAAA ATAGGA CTATAG GCAAGA CTGTTG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0096] <h2 style=";text-align:left;direction:ltr"> GACATTTTCTTA ATTAGT GATGGA TGTGGG AGGGCC CAGACC ATTGTG GGTGGT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0097] <h2 style=";text-align:left;direction:ltr"> GCGATC TCTGTCCTGGGT TCTATA AGAAAG CAGGCT GAGCAA GCTATG GGGAGC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0098] AAGCCA GTAAGC AGCACCCCTTCA TGGCCT CTGCAT CAGCTT CTGCCT CCAAGT
[0099] TCCTGT CCAGTT TGACTT CCTGTCCAGACT TCCTCC AATGCT GAACAG CGATGT
[0100] GGAAAT GTAAGC CAGTAA ACCCTT GCTTTGGTTGGT ATTTCA TCATAG CAATGC
[0101] AAACCT TGACTT AGGCAA TCCCTA CATTGA TGCAGATAGGTT GAGATT TAGATC
[0102] TATTCT TCCATT ACTTGC TGCTGG TATTGA ATGTCA GCACAGGGACTA TGGTAA
[0103] GACAGC TTTCTT TTCATA CTGTTT TGAAGT CAAAGT CTTAAA GTGATAAGACATTTTTTTCCTCAT ACTTGT TTTAAT AGTAAG GCTTTA ATATCT AAGGCTAGACATTCAACA TTTCCC TGATACCCAGAG ACTATT ACTCTA GGACAA TTGACTCTGTTT CTACATGCATTT TCTTTT ATTATG TTTATTTATTTT ATGGGC ATGAGTATTTTG TTTGCA TGTACTTATGCA CAATAC GTAAGT GCAGTG CCTAAGGAAGCCAGAAGA AGGTAT TGGATC CCTTGGAAATGA AGTTAC AGATGG CTGTGA GCTCCTGTGTGAATGCTG GGGCCC AAACTA AGGTCCTCTGCA AGTGCC TTCGGT ACTCTTAACCTT TGAGCC ATCCCTCCAGTC TACACA CTTTCATGAAGC TTCCAC TACCCCACCTTA GCTCCA GGAACT AGCAGC ACTACCAGCCCT GACCCAGCTTCC TGTGAATCCATG GATAAA AGACAC ACAGAC ACACAC AGGTTG CTCATTTTCAACTAGCCTTCTGAC ACAATT GCTGGG TGCTGC TATCTC CCGTCT GGAAAAGTGTGCCCTTATCAGTAT TCTTAG CTCTGT ACCTCC CACCTG CCCTAA ACTTTA GTTTGATCAGTTACATCTAGTCCCT GTTAAC ATCCCT GACAGA CACACA GGCTGC CACTCCTCCCTC GATCTCACATGGCTTCTT GGCTTT TCTCTC TCTGAA GCATGG TGAACTCCTCCCTT(SEQ ID NO.5)
[0104] Preferably, the RAB31 inhibitor is a nucleic acid construct, and the nucleic acid construct comprises the nucleic acid molecule described above.
[0105] More preferably, the method for constructing the nucleic acid construct is: using BAC clone RP24-36513 as a template, generating homology arms and knockout regions by PCR. Connecting two loxP sites in the same direction on both sides of exon 2 of the RAB31 gene and connecting them to the left homology arm; connecting the Neo selection marker between two self-deletion anchors (SDA), 5 ’ The right loxP site is connected to the 3 ’ The sequence of the nucleic acid construct is shown in SEQ ID No.6.
[0106] The PCR primer sequences used are:
[0107] F1: 5'-TCCCTTATATCAGCGAAACAGCCA-3' (SEQ ID No. 7)
[0108] R1: 5'-AGCAAGCTTCCCAGACAGTC-3' (SEQ ID No. 8)
[0109] Preferably, the RAB31 inhibitor is a gene editing system, and the gene editing system is selected from one or more of the Cre-Loxp system, the Flp-FRT system, the Dre-ROX system, the vCre-vloxp system, the sCre-sloxp system, the CRISPR / Cas9 system, the CRISPR / Cas12 system, and / or a CRISPR / Cas derived single base editing system. The gene editing system uses the sequence shown in SEQ ID No.1 as the target sequence (knockout region or cKO region) for knockout. In certain specific embodiments, the RAB31 inhibitor is a Cre-Loxp system, and the Cre-Loxp system comprises the targeting vector described above, and the targeting vector knocks out the RAB31 gene under the action of the Cre recombinase.
[0110] Preferably, the RAB31 inhibitor has the effect of preventing and / or treating myocardial infarction through at least one of the following:
[0111] Reduce inflammatory infiltration of myocardial cells;
[0112] Reduce cardiomyocyte loss;
[0113] Inhibits cardiac function decline;
[0114] Inhibit myocardial fibrosis;
[0115] Improve cardiac remodeling after myocardial infarction.
[0116] In the acute phase of myocardial infarction (AMI), the myocardium in the infarcted area shows coagulative necrosis, the myocardial interstitium is congested and edematous, and a large number of inflammatory cells are infiltrated. After the acute phase, as the collagen matrix supporting myocardial cells decomposes, the necrotic myocardial cells slip, and the necrotic tissue stretches and then thins, which is one of the causes of early left ventricular dilatation. The myocardial interstitium in the non-necrotic area is also remodeled due to the influence of neuroendocrine, resulting in impaired contraction and relaxation of the heart and ultimately leading to heart failure. After myocardial infarction, only a small number of myocardial cells divide and proliferate, and the myocardial tissue cannot be effectively and completely repaired. Therefore, the myocardium in the infarcted area can only undergo ventricular remodeling through the proliferation of fibrous tissue and the replacement of scar tissue without contractile function, which in turn causes severe arrhythmias, heart failure, and even death. The present application found that knocking out the RAB31 gene can significantly inhibit the left ventricular ejection fraction (LVEF) and the left ventricular short-axis contraction rate (LVFS), indicating that knocking out RAB31 can significantly inhibit the cardiac function decline caused by myocardial infarction; through HE staining, it was found that knocking out the RAB31 gene can reduce the number of cardiomyocytes, reduce inflammatory infiltration, and reduce the cardiac index; through Masson staining, it was found that knocking out the RAB31 gene can inhibit myocardial fibrosis, comprehensively achieve the improvement and treatment of ventricular remodeling after myocardial infarction, and effectively treat cardiovascular diseases, especially myocardial infarction.
[0117] Another aspect of the present invention also protects a nucleic acid molecule for reducing the expression of the RAB31 gene, wherein the target sequence of the nucleic acid molecule comprises that shown in SEQ ID NO.1.
[0118] Preferably, loxp is connected to the upstream of the target sequence, and loxp is connected to the downstream of the target sequence, forming: loxp-target sequence-loxp.
[0119] More preferably, the first segment of loxp is connected to the upstream of the first homology arm, the second segment of loxp is connected to the downstream of the second homology arm, and a positive screening marker is provided between the two Loxp sequences. The positive screening marker is Neo. There are SDA sites on both sides of the positive screening marker.
[0120] Further preferably, a negative screening marker is connected upstream of the first homology arm, and the negative screening marker is DTA.
[0121] In a specific embodiment, the nucleic acid molecule comprises DTA-first homology arm-LoxP-target sequence-SDA-Neo-SDA-LoxP-second homology arm.
[0122] Another aspect of the present invention also protects substances related to the nucleic acid molecules described above, and the substances include one or more of the following: 1) a nucleic acid construct, the nucleic acid construct comprising the nucleic acid molecule described above; 2) a gene editing system, the gene editing system uses the nucleic acid molecule described above as a target sequence and knocks out; or, contains the nucleic acid construct described in 1); 3) a cell line, the cell line comprises the nucleic acid molecule described above; or, contains the nucleic acid construct described in 1); or, the cell line is obtained by transfecting a host cell with the gene editing system described in 2); 4) a pharmaceutical composition, the pharmaceutical composition comprises the nucleic acid construct described in 1); or, the gene editing system described in 2); or, contains the cell line described in 3). Preferably, the nucleic acid construct (targeting vector) can be obtained by cloning the nucleic acid molecule encoding the above into a known vector. The known vector is a bacterial artificial chromosome BAC. Those skilled in the art can construct and obtain it using conventional methods for targeting expression vectors. For example, the target sequence is inserted into a plasmid containing Loxp, Neo and DTA by homologous recombination to form the nucleic acid construct. The nucleic acid construct comprises DTA-first homology arm-LoxP-target sequence-SDA-Neo-SDA-LoxP-second homology arm, and the sequence of the formed nucleic acid construct is as shown in SEQ ID NO.6.
[0123] Preferably, the gene editing system is a Cre-Loxp system, and the Cre-Loxp system comprises the nucleic acid construct (targeting vector) described above.
[0124] Preferably, the cell line refers to ES cells as host cells, and the gene editing system is transfected to knock out the RAB31 gene in the host cell. The ES cells are C57BL / 6NES cells. For example, the targeting vector in the gene editing system is linearized by enzyme cutting, and then the host cell is transfected by electroporation.
[0125] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient means that when the drug is properly administered to an animal or a human, they will not produce adverse, allergic or other adverse reactions. The pharmaceutically acceptable excipient should be compatible with the substance that inhibits RAB31, that is, it can be blended with it without significantly reducing the effect of the substance that inhibits RAB31 under normal circumstances. The pharmaceutically acceptable excipient is selected from one or more of a carrier, a diluent, a binder, a lubricant and a wetting agent. Specific examples of some substances that can be used as pharmaceutically acceptable carriers, diluents, binders, lubricants and wetting agents are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium methylcellulose, ethylcellulose and methylcellulose; tragacanth powder; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyols, such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; emulsifiers, such as Tween; wetting agents, such as sodium lauryl sulfate; colorants; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline solution; and phosphate buffers, etc. These substances are used as needed to help the stability of the formulation or to help improve the activity or its biological effectiveness or to produce an acceptable taste or smell in the case of oral administration. The dosage form of the composition is one or more of solution, injection, spray, nasal drops, aerosol, powder spray, tablet, capsule and granule. The composition can be introduced into the body such as muscle, intradermal, subcutaneous, intravenous, mucosal tissue by injection, spray, nasal drops, eye drops, penetration, absorption, physical or chemical mediation; or introduced into the body after being mixed or wrapped with other substances. Preferably, it is administered intraperitoneally. The drug can also be used in combination with other treatment methods, including surgery, radiotherapy, chemotherapy, and targeted therapy.
[0126] Another aspect of the present invention also protects the use of the nucleic acid molecules or substances described above in preparing a kit for preventing or treating cardiovascular diseases; and / or preparing a kit for reducing the expression of the RAB31 gene.
[0127] Preferably, the product for preventing or treating cardiovascular diseases has at least one of the following effects: reducing inflammatory infiltration of myocardial cells; reducing myocardial cell loss; inhibiting cardiac function decline; inhibiting myocardial fibrosis; and improving ventricular remodeling after myocardial infarction.
[0128] Another aspect of the present invention also protects a method for screening drugs for preventing and / or treating myocardial infarction caused by cardiovascular diseases, the method comprising: taking RAB31 as a drug target, and searching for substances that can inhibit or block the expression and / or function of RAB31 as candidate drugs.
[0129] Preferably, an in vitro cell model or animal model with overexpression of the RAB31 gene is constructed, the drug to be selected is applied to the in vitro cell model or animal model, and then the content of RAB31 is detected. The cells may be from mammals
[0130] The experimenter can determine whether the candidate drug is a drug with therapeutic significance by detecting the content of RAB31. Generally speaking, compared with the control group, a drug that can reduce the content of RAB31 by 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100% can be determined as a drug with therapeutic significance.
[0131] In the present invention, the cardiovascular disease is ischemic heart disease, including myocardial infarction, arrhythmia, and coronary atherosclerotic heart disease. Preferably, it is myocardial infarction. Myocardial infraction (MI) refers to local myocardial necrosis caused by persistent and severe ischemia in the heart of the blood supply area due to blockage of the coronary artery and interruption of blood flow.
[0132] The following is a description of the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0133] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are intended to describe specific embodiments, rather than to limit the scope of protection of the present invention. The test methods in the following examples without specifying specific conditions are generally carried out under conventional conditions or under conditions recommended by the manufacturers.
[0134] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
[0135] In the following examples of the present application, C57BL / 6 male mice were SPF grade, weighing 20-25±3 g, and provided by Shanghai Slake Laboratory Animal Center, with the experimental animal use license number: SYXK(Min)2014-0001.
[0136] Example 1 Construction of RAB31 knockout mice
[0137] The method for constructing the targeting vector for knocking out RAB31 in the present invention is as follows Figure 4 As shown, a targeting construct spanning the exons of RAB31 was used to generate Rab31 flox mice. Briefly, the construct includes loxP-target sequence-loxP cassette to construct a targeting vector for RAB31. The constructed targeting vector was electroporated into embryonic stem cells to construct ES clones, and the ES clones were screened by PCR. The correct clones were obtained, injected into blastocysts, and finally constructed to obtain homozygous mice with RAB31 gene knockout.
[0138] 1.1. Construction of gene knockout targeting vector
[0139] The mouse RAB31 gene is located on mouse chromosome 7; a total of 7 exons have been identified, starting from the start codon ATG in exon 1 and ending with the stop codon TGA in exon 7 (Transcript: ENSMUST00000070673).
[0140] Exon 2 was selected as the conditional knockout region (cKO region), the deletion of which should result in loss of function of the mouse RAB31 gene.
[0141] The sequence of exon 2 is shown in SEQ ID No.1.
[0142] Using RP24-36513 from the C57BL / 6N mouse library BAC clone as a template, the homology arms and conditional knockout region (cKO region) of the RAB31 gene were generated by PCR. The PCR primer sequences used were:
[0143] F1: 5'-TCCCTTATATCAGCGAAACAGCCA-3' (SEQ ID No. 7)
[0144] R1: 5'-AGCAAGCTTCCCAGACAGTC-3' (SEQ ID No. 8)
[0145] The nucleic acid molecule generated by PCR comprises the following elements: a first homology arm - exon 2 and a second homology arm.
[0146] The process of constructing the targeting vector is as follows: insert two LoxP sites on both sides of exon 2 of the mouse RAB31 gene, insert two SDA (self-deletion anchor) sites and a Neo positive selection marker element, and finally ’ Homology arm (i.e. first homology arm) 5 ’The DTA negative selection marker element is inserted into the end. The targeting vector contains the following elements: DTA-first homology arm-LoxP-Exon 2-SDA-Neo-SDA-Loxp-second homology arm. Neo is the neomycin resistance gene, which serves as a positive selection marker; DTA is the toxin gene, which serves as a negative selection marker; SDA is the self-deletion anchor.
[0147] The LoxP sequence is shown in SEQ ID NO.2, the SDA sequence is shown in SEQ ID NO.3, the first homology arm is shown in SEQ ID NO.4, the second homology arm is shown in SEQ ID NO.5, and the sequence of the targeting vector is shown in SEQ ID No.6.
[0148] The targeting vector is linearized using an enzyme. The schematic diagram of the linearized targeting vector is shown in Figure 5 .
[0149] 1.2. ES targeting and screening: The linearized targeting vector is introduced into mouse ES cells by electroporation. After overnight culture, positive and negative screening is performed, and the positive recombinant ES cells are retained for injection into the blastocyst cavity of recipient mice.
[0150] 1.3. Blastocyst injection: The positive cell clones that have undergone homologous recombination are injected into the 3.5-day blastocysts of C57BL / 6N donor mice, and the blastocysts are transplanted into the uterus of CD-1 pseudo-pregnant mice to produce F0 generation positive chimeric mice.
[0151] 1.4. Obtaining homozygous offspring: F0 positive mice were bred with tissue-specific Cre mice (WT wild-type mice with cre enzyme, Saiye Biotechnology Co., Ltd.) at a rate of 1♂ and 2♀Cre to obtain F1 mice (flox / + ,Cre) and F1 mice (flox / + ), identification; F1 generation mice (flox / + ,Cre) and F1 mice (flox / + )) 1♂×2♀Cre was used to breed F2 mice (flox / flox ,Cre) and F2 mice (flox / flox ), F2 generation mice (flox / flox ) is also Rab31 - / - (KO) mice were raised to 8-10 weeks of age for the next experiment.
[0152] flox / + : Indicates that the locus is heterozygous, that is, one allele has a flox site and the other is a wild-type allele. / flox: Indicates that the locus is double flox, with both alleles carrying flox sites.
[0153] Example 2
[0154] In this example, the changes in cardiac function, cardiac pathological morphology and myocardial fiber in mice after RAB31 gene knockout were investigated.
[0155] These include:
[0156] 2.1 Experimental Materials
[0157] 2.1.1 Experimental Animals
[0158] The RAB31 knockout mice constructed in Example 1 were raised and bred in the SPF animal center of our school.
[0159] Animal experiments were conducted in accordance with the Guidelines for the Treatment of Laboratory Animals issued by the Ministry of Science and Technology in 2006 and the Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health.
[0160] The mice were placed in the SPF laboratory of the Specific Non-Pathogenic Laboratory Animal Center of Fujian University of Traditional Chinese Medicine, and were raised freely to eat and drink. The room was well ventilated and illuminated, the room temperature was controlled at (25±1)℃, the relative humidity was about 60%, and the light / dark cycle was 12h. The mice were allowed to adapt to these conditions for at least 7 days before the experiment. The breeding environment was kept quiet and undisturbed.
[0161] 2.1.2 Experimental drugs and main reagents
[0162] Eosin staining solution (Beijing Solebow Technology Co., Ltd. Cat No. G1100-500); hematoxylin staining solution (Beijing Solebow Technology Co., Ltd. Cat No. G1140-500); isoflurane (Shenzhen Ruiwode Life Science Co., Ltd. Cat No. R510-22); paraformaldehyde (Beijing Solebow Technology Co., Ltd. Cat No. LA0427), anhydrous ethanol (Xilong Chemical Co., Ltd. Cat No. 64-17-5), xylene (Sinopharm Chemical Reagent Co., Ltd. Cat No. 2052-46-2).
[0163] 2.1.3 Main instruments of the experiment
[0164] Small animal ultrasound imaging system Vevo2100 (Fujifilm Investment Co., Ltd.); inhalation small animal anesthesia machine (Shenzhen Ruiwode Life Science Technology Co., Ltd.); pathology slicer (Germany Leica); paraffin embedding machine (Hubei Xiaogan Yaguang Medical Electronic Technology Co., Ltd.); biological tissue automatic dehydration machine (Hubei Xiaogan Yaguang Medical Electronic Technology Co., Ltd.).
[0165] 2.2 Experimental Methods
[0166] 2.2.1 Animal grouping and intervention
[0167] Male wild-type WT mice (Rab31 + / + ) were randomly divided into 2 groups, WT+Sham group (n=6) and WT+MI group (n=6). The WT+MI group refers to the WT mice model of myocardial infarction (MI) induced by ligation of the left anterior descending coronary artery (LAD), i.e. MI surgery+ and Rab31 + / + WT+Sham refers to WT mice without LAD ligation after thoracotomy, i.e., MIsurgery- and Rab31 + / + .
[0168] At the same time, male KO mice (Rab31 - / - ) were randomly divided into 2 groups, KO+Sham group (n=6) and KO+MI group (n=6). The KO+MI group refers to the KO mice model of myocardial infarction (MI) induced by ligation of the left anterior descending coronary artery (LAD), i.e., MI surgery+ and Rab31 - / - KO+Sham means that the LAD was not ligated after thoracotomy in KO mice, i.e., MI surgery- and Rab31 - / - .
[0169] The myocardial infarction (MI) model was established by ligating the left anterior descending coronary artery: the mouse was placed in a supine position, the muscles between the third and fourth ribs on the left were bluntly separated, the third and fourth ribs were propped open with hemostats, and the heart was quickly squeezed out. The left anterior descending coronary artery was ligated with a 6-0 suture needle. The ligation position was 1mm below the left atrial appendage, and the needle insertion depth was 0.5mm. During the operation, the myocardium in the myocardial infarction area below the ligation site turned pale to determine whether the ligation was successful. The electrocardiogram was connected to further determine whether the model was successful. After surgery, penicillin was routinely injected intraperitoneally at 100,000 / U per mouse per day for 3 consecutive days. The incision skin was also disinfected to prevent infection.
[0170] The cardiac function of each group was measured in the second week after surgery, and the experiment was terminated after 2 weeks.
[0171] 2.2.3 Small animal ultrasound detection of mouse cardiac function
[0172] The cardiac function of mice was tested using Vevo 2100 animal ultrasound in the second week after surgery (7 days after myocardial infarction). The experimental animals were fixed on a 37°C constant temperature heating plate in a supine position under 2% isoflurane inhalation anesthesia. After the chest hair was removed, the probe was placed on the chest with a probe frequency of 400MHz. Parasternal long axis sections and left ventricular short axis sections were collected, and M-mode ultrasound was used to record the left ventricular movement at the posterior edge of the papillary muscle. The measurement indicators included: left ventricular end-diastolic diameter (LVED; d) and left ventricular end-systolic diameter (LVES; d); and the left ventricular ejection fraction (LVEF) and left ventricular short axis contraction fraction (LVFS) were calculated to compare the changes in cardiac function of mice in each group.
[0173] The left ventricular ejection fraction (LVEF) and short-axis contraction fraction (LVFS) were calculated as follows:
[0174] LVEF (%) = (LV Vol; d – LV Vol; s) / LV Vol; d × 100%
[0175] LVFS(%)=(LVID;d-LVID;s) / LVID;d×100%
[0176] 2.2.4 HE staining
[0177] The mouse heart was taken on the 14th day after myocardial infarction surgery, fixed in 4% paraformaldehyde for 24 hours, and then dehydrated with low to high concentrations of anhydrous ethanol. The tissue block was then placed in xylene to make it transparent, and the alcohol in the tissue block was replaced with xylene. After wax immersion, the vascular tissue was embedded in paraffin and cooled to solidify into a block. The embedded wax block was fixed on a slicer and cut into 4μm slices. The sliced slices were ironed in 37℃ water, then attached to a glass slide, and baked at 60℃ for 1h to make paraffin sections. The tissue sections were transparentized in xylene I and II and rehydrated in an ethanol gradient. The samples were stained in hematoxylin solution for 1min, eosin solution for 10s, dried, sealed with neutral gum, and the pathological morphological changes of the heart were observed under a microscope.
[0178] 2.2.5 Masson staining
[0179] The paraffin sections of mouse hearts fixed 14 days after myocardial infarction were taken, and after tissue dehydration, embedding, and slicing, the sections were treated with xylene for transparency, gradient dewaxing with ethanol, and washed with tap water and distilled water in sequence. Then, the nuclei were stained with Regaud hematoxylin or Weigert hematoxylin for 5-10 minutes, washed thoroughly with water, and then with Masson ponceau acid red solution for 5-10 minutes, and then immersed in 2% glacial acetic acid aqueous solution for a while, differentiated with 1% phosphomolybdic acid aqueous solution for 3-5 minutes, and then directly stained with aniline blue or light green solution for 5 minutes without washing, and then immersed in 0.2% glacial acetic acid aqueous solution, dehydrated with 95% alcohol and anhydrous alcohol, transparentized with xylene, sealed with neutral gum, and the changes in the degree of fibrosis were observed under a microscope.
[0180] 2.2.6 Statistical analysis
[0181] The experimental data were expressed as mean ± standard deviation (X ± s) and analyzed using SPSS18 software. The t test was used to compare the means between two groups, and the one-way analysis of variance was used to compare the means between multiple groups. P < 0.05 was considered statistically significant.
[0182] 2.3 Experimental Results
[0183] 2.3.1 Effects of RAB31 knockout on cardiac function in mice with myocardial infarction
[0184] The cardiac function of mice was detected in the second week after surgery, and small animal ultrasound was used to detect the effects of RAB31 knockout on the left ventricular end-diastolic diameter (LVED; d), left ventricular end-systolic diameter (LVES; d), left ventricular ejection fraction (LVEF), and left ventricular short-axis contraction fraction (LVFS) of mice.
[0185] Figure 1A For cardiac ultrasound; Figure 1B It is a statistical graph of left ventricular ejection fraction (LVEF); Figure 1C This is a statistical chart showing the left ventricular fractional contraction (LVFS). LVEF and LVFS can reflect heart function, and low values represent poor heart function.
[0186] from Figures 1A-1C It can be seen that compared with the WT+Sham group, the LVEF and LVFS of the WT+MI group were significantly decreased, and the difference was statistically significant (P < 0.05); compared with the WT+MI group, the LVEF and LVFS of the KO+MI group were significantly increased, and the difference was statistically significant (P < 0.05), indicating that knocking out RAB31 significantly inhibited the cardiac function decline caused by myocardial infarction.
[0187] 2.3.2 Effects of Rab31 knockout on cardiac pathology in mice with myocardial infarction
[0188] HE staining was used to compare the cardiac pathological changes of mice in each group. Figure 2A shown.
[0189] from Figure 2A It can be seen that compared with the WT+Sham group, the WT+MI group had a large number of cardiomyocytes missing and inflammatory cells infiltrated; compared with the WT+MI group, the KO+MI group still had a large number of cardiomyocytes and the inflammatory infiltration was alleviated.
[0190] The changes in the heart index of mice in each group were further measured. That is, the mouse heart was taken on the 14th day after acute myocardial infarction, the excess vascular connective tissue at the bottom of the heart was trimmed in ice PBS, and the water on the heart was wiped dry with filter paper, and the heart was weighed and HW was recorded. The tibia was taken out, and the tibia length TL was measured with a vernier caliper, and the heart index (heart index) = heart weight (HW) / tibia length (TL) was calculated.
[0191] After a myocardial infarction, the heart weight will increase, and the severity of the myocardial infarction can be reflected by calculating the changes in the cardiac index.
[0192] The cardiac index results of different groups are shown in Figure 2B .
[0193] As shown in 2B, compared with the WT+Sham group, the cardiac index of the WT+MI group was significantly increased. Compared with the WT+MI group, the cardiac index of the KO+MI group was decreased, and the difference was statistically significant (P<0.05), indicating that RAB31 knockout can inhibit the increase of cardiac index caused by myocardial infarction.
[0194] In summary, RAB31 knockout can improve the pathological morphological changes of the heart caused by myocardial infarction.
[0195] 2.3.3 Effect of RAB31 knockout on myocardial fibrosis in mice with myocardial infarction
[0196] Masson staining was used to detect the changes in cardiac fibrosis in each group of mice. The staining results are shown in 3A and the statistical results are shown in Figure 3B .
[0197] from Figure 3A It can be seen that compared with the WT+Sham group, a large amount of collagen was deposited in the myocardial tissue of the WT+MI group; compared with the WT+MI group, the collagen deposition in the KO+MI heart tissue was significantly reduced, indicating that RAB31 knockout can improve myocardial fibrosis caused by myocardial infarction.
[0198] from Figure 3B It can be seen that further statistics of the area of each group revealed that RAB31 knockout can improve myocardial fibrosis caused by myocardial infarction.
[0199] In summary, the present invention found that RAB31 knockout can significantly reduce the cardiac dysfunction caused by MI and alleviate myocardial fibrosis caused by MI, suggesting that RAB31 is an important target for the treatment of ventricular remodeling after myocardial infarction.
[0200] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. Use of a RAB31 inhibitor in the preparation of a drug for preventing and / or treating myocardial infarction, wherein the RAB31 inhibitor is selected from a nucleic acid molecule, and the nucleic acid molecule comprises the following elements: DTA-first homology arm-LoxP-exon 2-SDA-Neo-SDA-LoxP-second homology arm; wherein DTA, LoxP, and SDA are conventional sequences of targeting technology, the first homology arm is intron 1 of RAB31, and the second homology arm is intron 2 of RAB31; the exon 2 is the sequence shown in SEQ ID NO: 1; the first homology arm is the sequence shown in SEQ ID NO: 4; and the second homology arm is the sequence shown in SEQ ID NO:
5.
2. Use of a RAB31 inhibitor in the preparation of a medicament for preventing and / or treating myocardial infarction, wherein the RAB31 inhibitor is selected from a nucleic acid construct comprising the nucleic acid molecule described in claim 1.
3. Use of a RAB31 inhibitor in the preparation of a medicament for preventing and / or treating myocardial infarction, wherein the RAB31 inhibitor is selected from a gene editing system, and the gene editing system comprises the nucleic acid construct described in claim 2.
4. Use of a RAB31 inhibitor in the preparation of a medicament for preventing and / or treating myocardial infarction, wherein the RAB31 inhibitor is selected from a cell line, wherein the cell line is obtained by transfecting a host cell with the nucleic acid molecule of claim 1 or the nucleic acid construct of claim 2 or the gene editing system of claim 3.
5. Use of a RAB31 inhibitor in the preparation of a medicament for preventing and / or treating myocardial infarction, wherein the RAB31 inhibitor is selected from a pharmaceutical composition, the pharmaceutical composition comprising the nucleic acid molecule of claim 1 or the nucleic acid construct of claim 2 or the gene editing system of claim 3 or the cell line of claim 4; and a pharmaceutically acceptable excipient.
6. The use according to any one of claims 1 to 5, characterized in that The RAB31 inhibitor has the effect of preventing and / or treating cardiovascular diseases through at least one of the following: Reduce inflammatory infiltration of myocardial cells; Reduce cardiomyocyte loss; Inhibits cardiac function decline; Inhibit myocardial fibrosis; Improve cardiac remodeling after myocardial infarction.
7. A nucleic acid molecule for reducing RAB31 gene expression, characterized in that: The nucleic acid molecule comprises the following elements: DTA-first homology arm-LoxP-exon No. 2-SDA-Neo-SDA-LoxP-second homology arm; wherein DTA, LoxP, and SDA are conventional sequences of targeting technology, the first homology arm is intron No. 1 of RAB31, and the second homology arm is intron No. 2 of RAB31; the exon No. 2 is the sequence shown in SEQ ID NO: 1; the first homology arm is the sequence shown in SEQ ID NO: 4; and the second homology arm is the sequence shown in SEQ ID NO:
5.
8. Use of the nucleic acid molecule according to claim 7 in preparing a kit for reducing the expression of the RAB31 gene.
